stockrowLexaria Bioscience Corp.
LEXX Healthcare Biotechnology
Lexaria Bioscience Corp.’s revenue for fiscal 2025 (year ended August 2025) was $705,900.00, up 52.0% from fiscal 2024.
- Revenue
- −89.1%
- EPS
- +61.9%
- Free cash flow
- +53.9%
Quarter to May 2026, against a year earlier
Follow LEXX
Alert me
Lexaria Bioscience Corp. (LEXX) EV/Sales
As of 5 November 2026, Lexaria Bioscience Corp. (LEXX) trades at a EV/Sales of 6.1×. Over the past ten years it has ranged from 0.0× (February 2018) to 462× (April 2018); the current reading is higher than 14% of that period. That is below the Biotechnology industry median of 9.0× and above the Healthcare sector median of 3.5×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 19.9× | (76.14%) |
| FY2024 | 83.4× | 240.79% |
| FY2023 | 24.5× | (44.85%) |
| FY2022 | 44.4× | 105.45% |
| FY2021 | 21.6× | (75.32%) |
| FY2020 | 87.5× | (60.51%) |
| FY2019 | 222× | (33.15%) |
| FY2018 | 332× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Feb 2026 | 22.4× | 12.69% |
| Aug 2025 | 19.9× | (8.04%) |
| May 2025 | 21.6× | (40.95%) |
| Feb 2025 | 36.7× | (37.85%) |
| 31 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| VTGN VistaGen Therapeutics, Inc. compare | −6.4× |
| MTVA MetaVia Inc. compare | n/m |
| NKGN NKGen Biotech, Inc. compare | n/m |
| CMMB Chemomab Therapeutics Ltd. Sponsored ADR compare | n/m |
| MBRX Moleculin Biotech, Inc. compare | n/m |
| LTRN Lantern Pharma Inc. compare | n/m |
| TOVX Theriva Biologics, Inc. compare | n/m |
| ACTU Actuate Therapeutics, Inc. compare | n/m |
| LEXX Lexaria Bioscience Corp. | 6.1× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.5× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)